We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Malin Corporation Plc | LSE:0Y71 | London | Ordinary Share | IE00BVGC3741 | MALIN CORPORATION ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Offices-holdng Companies,nec | 0 | 0 | - | N/A | 0 |
TIDM0Y71
RNS Number : 7366J
Malin Corporation PLC
28 April 2022
Malin Corporation plc
Viamet's Successor Company, Mycovia, announces FDA approval of VIVJOA(TM) (otesecanazole) for the treatment of recurrent vulvovaginal candidiasis
-- VIVJOA(TM) is the first and only FDA approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC) (Chronic Yeast Infection)
-- Mycovia expects to commercially launch the drug in the United States during Q2 2022.
Dublin-Ireland, 28 April 2022 : Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies, is pleased to note that Mycovia, the successor company to Malin's investee company Viamet, has announced the approval from the United States Food and Drug Administration (FDA) of VIVJOA(TM) (otesecanazole) for the treatment of RVVC in females with a history of RVVC and who are not of reproductive potential.
Mycovia is planning its commercial launch of VIVJOA(TM) in the second quarter of 2022.
"The approval of VIVJOA(TM) in the US is a significant milestone and is based on the excellent efficacy and safety data reported by Mycovia from its three Phase 3 trials of otesecanazole including 875 patients across 11 countries," said Darragh Lyons, Malin Chief Executive Officer. "The approval will result in the initiation of recurring cash inflows from milestone payments and royalties to Malin as a Viamet shareholder before the end of 2022."
Malin owns approximately 15% of Viamet.
A copy of Mycovia's press release is available to view at the following link:
http://www.rns-pdf.londonstockexchange.com/rns/7366J_1-2022-4-28.pdf
This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) No 596/2014 (MAR).
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com
For further information please contact:
Malin
Fiona Dunlevy, Company Secretary
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
Liberum (Joint Broker)
Phil Walker / Ben Cryer
Tel: +44 (0) 20 3100 2000
Powerscourt (Media enquiries)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFLFSLSLITFIF
(END) Dow Jones Newswires
April 28, 2022 08:05 ET (12:05 GMT)
1 Year Malin Chart |
1 Month Malin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions